Halozyme Therapeutics (HALO) Receivables - Net (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Receivables - Net data on file, last reported at $458.0 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $458.0 million, up 50.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $458.0 million (up 50.35% YoY), and the FY2025 annual result was $441.3 million, up 43.06% from the prior year.
• Receivables - Net climbed to $458.0 million in Q1 2026 per HALO's latest filing, from $441.3 million in the prior quarter.
• Over five years, Receivables - Net peaked at $458.0 million in Q1 2026 and troughed at $115.0 million in Q1 2022.
• A 5-year average of $265.6 million and a median of $233.3 million in 2022 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net jumped 150.85% in 2022, then dropped 6.85% in 2023.
• A 5-year view of Receivables - Net shows it stood at $231.1 million in 2022, then grew by 1.36% to $234.2 million in 2023, then jumped by 31.7% to $308.5 million in 2024, then jumped by 43.06% to $441.3 million in 2025, then rose by 3.79% to $458.0 million in 2026.
• Business Quant data shows HALO's Receivables - Net at $458.0 million in Q1 2026, $441.3 million in Q4 2025, and $346.0 million in Q3 2025.